ZyhCG (HCG (Human Chorionic Gonadotropin))

Medicine OverView

Product Code:
1039
Country of Origin :
India
Dosage Form :
Injection
Indication :
Female infertility
Packaging :
1 Vial in Box
Active Ingredient :
HCG (Human Chorionic Gonadotropin)
Manufacturer :
German Remedies Private Ltd
Select your dosage
Product of India
Manufactured by:
German Remedies Private Ltd

Free Delivery On $199 Or Above Of Cart Value
Select a Quantity
  • $48.00 ($16.00 per Injection)
  • $96.00 ($16.00 per Injection)
  • $114.00 ($12.67 per Injection)
More Options Below
Product of India
Manufactured by:
German Remedies Private Ltd

Free Delivery On $199 Or Above Of Cart Value
Select a Quantity
  • $60.00 ($20.00 per Injection)
  • $120.00 ($20.00 per Injection)
  • $180.00 ($20.00 per Injection)
More Options Below
Product of India
Manufactured by:
German Remedies Private Ltd

Free Delivery On $199 Or Above Of Cart Value
Select a Quantity
  • $75.00 ($25.00 per Injection)
  • $150.00 ($25.00 per Injection)
  • $225.00 ($25.00 per Injection)
More Options Below

ALTERNATIVE MEDICINE


Description

Buy HCG ( Human Chorionic Gonadotrophin ) 2000iu, 5000iu, 10000 iu Injection online at a reasonable price from most trusted pharmacy to cure Female infertility. Get all information regarding this medicine like a review, uses side effect, dosage ( Missed/Over ), Composition, Substitutes, Precautions, manufactured by German Remedies Private Ltd, India, how it works, how long does last. You can also get speedy delivery in UK, USA, France, Australia, China.

This Injection is a lyophilized preparation of human Chorionic Gonadotropin (hCG) - a gonad-stimulating polypeptide hormone secreted by the human placenta and obtained from the urine of pregnant women. The action of this medication is virtually identical to that of pituitary LH although hCG appears to have a little degree of FSH activity as well. It stimulates the production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testes to produce androgen and the corpus luteum of the ovaries to produce progesterone.this medicine is the composition of Mannitol I.P, Disodium hydrogen orthophosphate I.P., Sodium Dihydrogen orthophosphate I.P.

In the female:

Anovulatory infertility

this injection is used in the treatment of anovulatory infertility, where its administration would form part of a recognized treatment regimen involving the prior stimulation of follicular maturation and endometrial proliferation, e.g., with urofollitropin or menotrophin.

Superovulation for an assisted conception technique:

this medication may also be used of a regimen of ovarian stimulation in assisted conception techniques.

In the male:

  • Hypogonadotropic hypogonadism
  • Cryptorchidism
  • Oligo-asthenospermia and azoospermia

This medication must be administered parenterally since this injection is destroyed in the GI tract is a polypeptide. Following intramuscular injection, a detectable rise in serum hCG(Human Chorionic Gonadotropin) levels is seen in 2 hours; peak levels are reached in 6 hours and remain at this level for 36 hours. These injection levels begin to decline at the 48-hour approach baseline (undetectable) levels after 72 hours.

Following IM administration of this injection, this injection distributed mainly into the testes in males and the ovaries in females. Smaller amounts of the drug may be distributed into the proximal tubules of the renal cortex. Blood concentration of this injection decline in a biphasic manner.

The half-life in the initial phase is reported to be about 11, hours and in the terminal phase about 23 hours, About 10%-20% of a therapeutic dose of this injection is excreted in the urine within 24 hours, delectable amounts of the drug may be detected in the urine up to 3-4 days. For intramuscular and subcutaneous use only.

One vial of lyophilized Chorionic Gonadotrophin & one ampoule containing 2 ml of 0.9% w/v Sodium Chloride injection I.P. this injection Store Below 2 -8 ℃. Moreover, Protect from light & moisture. Use the reconstituted solution immediately after preparation.

hCG(ZyhCG) injection is given by intramuscular and subcutaneous injection only. The injection solution should be reconstituted with the solvent provided immediately before use.

In the female:

Anovulatory infertility

Up to 10,000 IU injection is given in mid-cycle, following treatment with urofollitropin or menotrophin according to a recognized treatment regimen.

Superovulation for an assisted conception technique:

Up to 10,000 IU injection is given in one single dose following the induction of multiple follicular developments after stimulation, according to a recognized treatment regimen. Egg retrieval is carried out 34-36 hours following this injection administration.

  • Corpus luteum insufficiency
  • 5000 IU injection is given on the 5th day after ovulation to be repeated on the 9th day.

  • Habitual abortion
  • Treatment should commence as soon as pregnancy is diagnosed and continue up to and including the 14th week of gestation in such cases, 10,000 IU injection should be given the first injection followed by 5000 IU twice weekly.

  • Threatened abortion
  • Similarly, patients presenting with a threatened abortion should receive 10,000 IU hCG on the first presentation followed by 5000 IU twice weekly until week 14 of gestation. Treatment should only commence if symptoms occur up to and including the 8th week of pregnancy.

In the male:

  • Hypogonadotropic hypogonadism
  • Human Chorionic Gonadotropin 2000 IU injection twice a week with the concomitant menotrophin administration, if necessary, for a minimum period of four months.

  • Cryptorchidism
  • hCG HP 500 IU to 1000 IU on alternate days for several weeks.

  • Oligo-asthenospermia and azoospermia
  • 500 IU hCG (ZyhCG) +75 IU mentrophin every day for three months or 2500 IU injection every five days and 75-150 IU menotrophin three times a week for three months or more.

Missed Dose

Take the missed dose as possible as you recall. Skip the dose if it is almost time for your next treatment. Do not take more medicine to make up the missed dose.

OverDose

Treatment must be symptomatic and supportive.

Human Chorionic Gonadotropin injection is generally well tolerated following administration of the usual therapeutic dose.

Minor side effect

Minor side effects are as follows

  • A headache
  • Irritability
  • Restlessness
  • Depression
  • fatigue or tiredness
  • aggressive behavior
  • Edema
  • pain at the site of injection

Major side effect

Major side effects are as follow.

  • precocious puberty
  • Gynaecomastia
  • ovarian hyperstimulation syndrome
  • enlargement of preexisting ovarian cysts and rupture
  • the growth of pubic hair
  • Cardiovascular
  • Arterial thromboembolism

General instructions/warning:

  • Since androgen secretion included by this injection may result in fluid retention, this injection should be used with caution in patients with asthma, epilepsy or seizure disorder, migraine, cardiac or renal disease.
  • Prepubertal males should be correctly monitored during hCG (ZyHCG)injection therapy since induction of androgen secretion by this injection may induce precocious puberty in these patients being treated for cryptorchidism. If signs of precocious puberty occur, the drug should be discontinued. These changes are reversible within four weeks the last injection.
  • In adult males and females, hormone levels of testosterone, dihydrotestosterone, 17阝-estradiol, 17阝hydroxyprogesterone, progesterone, androstenedione may be monitored depending on the nature of the diagnostic and therapeutic purpose.
  • This injection should be used in conjunction with menotrophin only by a physician who is experienced with infertility problems and who are familiar with the criteria for patients selection, and the cautions, precaution and contraindications associated with such therapy. The principal serious adverse effect associated with ZyhCG HP/menotrophin therapy include:
  • Ovarian hyperstimulation

Enlargement of pre-existing ovarian cysts or rupture of ovarian cysts resulting in hemoperitoneum.

Arterial thromboembolism is secondary to hyperestrogenism.

Increased incidence of multiple ovulations with resulting plural gestations and births.

During the first trimester of gestation. Not to be frozen.ZyhCG HP should not be administered to a woman who is breastfeeding.

When Not to Use

In patients with precocious puberty

In patients with carcinoma of the prostate or other androgen-dependent neoplasia

In patients who have experienced an allergic reaction to the drug

Warnings for special population

Pregnancy

this injection is not suggested for use in pregnant women.

Breastfeeding

This injection is not recommended for use in breastfeeding women.

No clinically significant drug interactions have been reported during ZyhCG HP therapy.

Products Reviews

Average Rating
5

5 star
4 star
3 star
2 star
1 star

(Based On 1 reviews Rating)

Write Review

What do you think about this product?

    Bad           Good

Safety & Securities